Hemin counteracts the repression of Bcl-2 and Nrf2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells

Oncology Research

Volumn 17, Issue 11-12, 2009, Pages 535-547

  Bonovolias, Ioannis D ^a   Tsiftsoglou, Asterios S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bcr Abl kinase; CML cells; Hemin; Imatinib mesylate; Protection

Indexed keywords

BCR ABL PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; GAMMA GLOBIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEME OXYGENASE 1; HEMIN; IMATINIB; PROTEIN BCL 2; PROTEIN BCL 2A; PROTEIN BCL 2B; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NFE2L2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL DIFFERENTIATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; GENE REPRESSION; HEME SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; PROTO ONCOGENE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA DAMAGE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENES, BCL-2; HEMIN; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NF-E2-RELATED FACTOR 2; PIPERAZINES; PYRIMIDINES;

EID: 70350485007     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504009789745557     Document Type: Article

References (52)

1. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:493-502; 2002.
2. Manley, P. W.; Cowan-Jacob, S. W.; Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 1754:3-13; 2005.
3. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355: 2408-2417; 2006.
4. Kuroda, J.; Puthalakath, H.; Cragg, M. S.; Kelly, P. N.; Bouillet, P.; Huang, D. C.; Kimura, S.; Ottmann, O. G.; Druker, B. J.; Villunger, A.; Roberts, A. W.; Strasser, A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. USA 103:14907-14912; 2006.
5. Barthe, C.; Cony-Makhoul, P.; Melo, J. V.; Mahon, J. R. Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163; 2001.
6. Graham, S. M.; Jorgensen, H. G.; Allan, E.; Pearson, C.; Alcorn, M. J.; Richmond, L.; Holyoake, T. L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325; 2002.
7. Weisberg, E.; Griffin, J. D. Resistance to imatinib (Glivec): Update on clinical mechanisms. Drug Resist. Update 6:231-238; 2003.
8. Melo, J. V.; Chuah, C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 249:121-132; 2006.
9. Jabbour, E.; Kantarjian, H.; Jones, D.; Talpaz, M.; Bekele, N.; O'Brien, S.; Zhou, X.; Luthra, R.; Garcia-Manero, G.; Giles, F.; Rios, M. B.; Verstovsek, S.; Cortes, J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767-1773; 2006.
10. Cowan-Jacob, S. W.; Guez, V.; Fendrich, G.; Griffin, J. D.; Fabbro, D.; Furet, P.; Liebetanz, J.; Mestan, J.; Manley, P. W. Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 4:285-299; 2004.
11. Desplat, V.; Belloc, F.; Lagarde, V.; Boyer, C.; Melo, J. V.; Reiffers, J.; Praloran, V.; Mahon, F. X. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer 103:102-110; 2005.
12. Barnes, D. J.; Palaiologou, D.; Panousopoulou, E.; Schultheis, B.; Yong, A. S.; Wong, A.; Pattacini, L.; Goldman, J. M.; Melo, J. V. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 65:8912-8919; 2005.
13. Khorashad, J. S.; Anand, M.; Marin, D.; Saunders, S.; Al-Jabary, T.; Iqbal, A.; Margerison, S.; Melo, J. V.; Goldman, J. M.; Apperley, J. F.; Kaeda, J. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20:658-663; 2006.
14. Illmer, T.; Schaich, M.; Platzbecker, U.; Freiberg-Richter, J.; Oelschlagel, U.; von Bonin, M.; Pursche, S.; Bergemann, T.; Ehninger, G.; Schleyer, E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401-408; 2004.
15. Lange, T.; Park, B.; Willis, S. G.; Deininger, M. W. BCR-ABL kinase domain mutations in chronic myeloid leukemia: Not quite enough to cause resistance to imatinib therapy? Cell Cycle 4:1761-1766; 2005.
16. Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed, M. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104:3739-3745; 2004.
17. Burchert, A.; Wang, Y.; Cai, D.; von Bubnoff, N.; Paschka, P.; Muller-Brusselbach, S.; Ottmann, O. G.; Duyster, J.; Hochhaus, A.; Neubauer, A. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19:1774-1782; 2005.
18. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880; 2001.
19. Mayerhofer, M.; Florian, S.; Krauth, M. T.; Aichberger, K. J.; Bilban, M.; Marculescu, R.; Printz, D.; Fritsch, G.; Wagner, O.; Selzer, E.; Sperr, W. R.; Valent, P.; Sillaber, C. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 64:3148-3154; 2004.
20. Shah, N. P.; Sawyers, C. L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22:7389-7395; 2003.
21. Mahon, F. X.; Belloc, F.; Lagarde, V.; Chollet, C.; Moreau-Gaudry, F.; Reiffers, J.; Goldman, J. M.; Melo, J. V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101: 2368-2373; 2003.
22. Burchert, A. Roots of imatinib resistance: A question of self-renewal? Drug Resist. Update 10:152-161; 2007.
23. Kirschner, K. M.; Baltensperger, K. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells. Mol. Cancer Res. 1:970-980; 2003.
24. Tsiftsoglou, A. S.; Tsamadou, A. I.; Papadopoulou, L. C. Heme as key regulator of major mammalian cellular functions: Molecular, cellular, and pharmacological aspects. Pharmacol. Ther. 111:327-345; 2006.
25. Tsiftsoglou, A. S.; Wong, W.; Wheeler, C.; Steinberg, H. N.; Robinson, S. H. Prevention of anthracycline-induced cytotoxicity in hemopoietic cells by hemin. Cancer Res. 46:3436-3440; 1986.
26. Tsiftsoglou, A. S.; Wong, W.; Robinson, S. H. Analysis of hemin-induced protection of human hemopoietic cells from the cytotoxic effects of anthracyclines. Cancer Res. 48:3566-3570; 1988.
27. Papadopoulou, L. C.; Tsiftsoglou, A. S. Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Biochem. Pharmacol. 52:713-722; 1996.
28. Ebert, P. S.; Hess, R. A.; Frykholm, B. C.; Tschudy, D. P. Succinylacetone, a potent inhibitor of heme biosynthesis: Effect on cell growth, heme content and delta-aminolevulinic acid dehydratase activity of malignant murine erythroleukemia cells. Biochem. Biophys. Res. Commun. 88: 1382-1390; 1979.
29. Beru, N.; Sahr, K.; Goldwasser, E. Inhibition of heme synthesis in bone marrow cells by succinylacetone: Effect on globin synthesis. J. Cell. Biochem. 21:93-105; 1983.
30. Lozzio, B. B.; Lozzio, C. B. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk. Res. 3:363-370; 1979.
31. Nakazawa, M.; Mitjavila, M. T.; Debili, N.; Casadevall, N.; Mayeux, P.; Rouyer-Fessard, P.; Dubart, A.; Romeo, P. H.; Beuzard, Y.; Kishi, K.; et al. KU 812: A pluripotent human cell line with spontaneous erythroid terminal maturation. Blood 73:2003-2013; 1989.
32. Sassa, S. Regulation of the genes for heme pathway enzymes in erythroid and in non-erythroid cells. Int. J. Cell Cloning 8:10-26; 1990.
33. Tsiftsoglou, A. S.; Hwang, K. M.; Agrawal, K. C.; Sartorelli, A. C. Strand-scission of Sarcoma 180 tumor cell DNA induced by 1-formylisoquinoline thiosemicarbazone. Biochem. Pharmacol. 24:1631-1633; 1975.
34. Rickwood, D.; Hames, B. D. In: Ormerod, M. G., ed. Flow cytometry: A practical approach. New York: Oxford University Press; 1990. 35
35. Mischiati, C.; Sereni, A.; Lampronti, I.; Bianchi, N.; Borgatti, M.; Prus, E.; Fibach, E.; Gambari, R. Rapamycin-mediated induction of gamma-globin mRNA accumulation in human erythroid cells. Br. J. Haematol. 126: 612-621; 2004.
36. Campanini, F.; Santucci, M. A.; Pattachini, L.; Brusa, G.; Piccioli, M.; Barbieri, E.; Babini, L.; Tura, S. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia. Haematologica 86:167-173; 2001.
37. Chou, Y. H.; Ho, F. M.; Liu, D. Z.; Lin, S. Y.; Tsai, L. H.; Chen, C. H.; Ho, Y. S.; Hung, L. F.; Liang, Y. C. The possible role of heat shock factor-1 in the negative regulation of heme oxygenase-1. Int. J. Biochem. Cell Biol. 37:604-615; 2005.
38. Crudden, G.; Chitti, R. E.; Craven, R. J. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J. Pharmacol. Exp. Ther. 316: 448-455; 2006.
39. Pabst, T.; Mueller, B. U.; Harakawa, N.; Schoch, C.; Haferlach, T.; Behre, G.; Hiddemann, W.; Zhang, D. E.; Tenen, D. G. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7:444-451; 2001.
40. Friedrich, M. G.; Weisenberger, D. J.; Cheng, J. C.; Chandrasoma, S.; Siegmund, K. D.; Gonzalgo, M. L.; Toma, M. I.; Huland, H.; Yoo, C.; Tsai, Y. C.; Nichols, P. W.; Bochner, B. H.; Jones, P. A.; Liang, G. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10:7457-7465; 2004.
41. Shen, J. C.; Klein, R. D.; Wei, Q.; Guan, Y.; Contois, J. H.; Wang, T. T.; Chang, S.; Hursting, S. D. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol. Carcinog. 29:92-102; 2000.
42. Pi, J.; Qu, W.; Reece, J. M.; Kumagai, Y.; Waalkes, M. P. Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp. Cell Res. 290:234-245; 2003.
43. Schaaf, G. J.; Maas, R. F.; de Groene, E. M.; Fink-Gremmels, J. Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. Free Radic. Res. 36:835-843; 2002.
44. Jeong, W. S.; Jun, M.; Kong, A. N. Nrf2: A potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox Signal. 8:99-106; 2006.
45. Mayerhofer, M.; Gleixner, K. V.; Mayerhofer, J.; Hoermann, G.; Jaeger, E.; Aichberger, K. J.; Ott, R. G.; Greish, K.; Nakamura, H.; Derdak, S.; Samorapoompichit, P.; Pickl, W. F.; Sexl, V.; Esterbauer, H.; Schwarzinger, I.; Sillaber, C.; Maeda, H.; Valent, P. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: A novel approach to overcome resistance against imatinib. Blood 111:2200-2210; 2008.
46. Hou, S.; Reynolds, M. F.; Horrigan, F. T.; Heinemann, S. H.; Hoshi, T. Reversible binding of heme to proteins in cellular signal transduction. Accounts Chemical Res. 39: 918-924; 2006.
47. Oyake, T.; Itoh, K.; Motohashi, H.; Hayashi, N.; Hoshino, H.; Nishizawa, M.; Yamamoto, M.; Igarashi, K. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol. Cell. Biol. 16: 6083-6095; 1996.
48. Appel, S.; Rupf, A.; Weck, M. M.; Schoor, O.; Brummendorf, T. H.; Weinschenk, T.; Grunebach, F.; Brossart, P. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin. Cancer Res. 11:1928-1940; 2005.
49. Nagai, T.; Kikuchi, S.; Ohmine, K.; Miyoshi, T.; Nakamura, M.; Kondo, T.; Furuyama, K.; Komatsu, N.; Ozawa, K. Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. J. Cell. Biochem. 104:680-691; 2008.
50. Bonovolias, I. D.; Manley, P. W.; Tsiftsoglou, A. S. Hemin confers resistance to imatinib (Glivec)-induced cell death but enhances nilotinib (AMN107) cytotoxicity in human K-562 CML leukemia cells. ASH Annual Meeting, USA; 2006:4769.
51. Jacquel, A.; Herrant, M.; Legros, L.; Belhacene, N.; Luciano, F.; Pages, G.; Hofman, P.; Auberger, P. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J. 17:2160-2162; 2003.
52. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3:1001-1010; 2004.